CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 7, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

Hematological Malignancies

Interventions

DRUG

Anti-CD7 CAR-T

Universal CAR-T cells targeting CD7

Trial Locations (1)

Institute of Hematology & Blood Diseases Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER